NCT05515406View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

ONO-7018

ONO-7018 tablet(s) are administered orally

DRUG

ONO-7018

ONO-7018 tablet(s) are administered orally

Trial Locations (10)

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

27858

Leo Jenkins Cancer Center/ECU School of Medicine, Greenville

37203

Sarah Cannon Research Institute, Nashville

45267

University of Cincinnati, Cincinnati

64114

AMR Kansas City, Kansas City

75246

Baylor Scott & White Research Institute, Dallas

77030

MD Anderson Cancer Center, Houston

90404

Jonsson Comprehensive Cancer Center, Santa Monica

98405

Northwest Medical Specialities, Tacoma

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT05515406 - A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | Biotech Hunter | Biotech Hunter